Rituximab monotherapy versus glucocorticoid therapy for adult minimal change disease: a retrospective study on noninferiority
Xiaoyun Li, Guoxiang Yao, Yujiao Sun, Na Li, Caifeng Gao, Haiping Wang, Rong Wang, Bing Chen · 2025
Read Rituximab monotherapy versus glucocorticoid therapy for adult minimal change disease: a retrospective study on noninferiority by Xiaoyun Li, Guoxiang Yao, Yujiao Sun, Na Li, Caifeng Gao, Haiping Wang, Rong Wang, Bing Chen (2025) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-12722937.txt.
Description
Xiaoyun Li and co-authors compared two drug strategies for a kidney condition in this 2025 records study. Minimal change disease floods the urine with protein and usually answers to steroids, but steroids carry heavy side effects. Rituximab, an antibody drug, might do the job alone. The team reviewed sixty biopsy-proven patients at one Chinese hospital treated from 2020 to 2024.
Twenty patients received rituximab alone; forty received steroids. None had prior immune therapy. Over twelve months, ninety-five percent reached remission and eighty percent reached complete remission, with fifteen percent relapsing. Forty percent reported side effects. The design tests whether the antibody is no worse than steroids at starting and holding remission, which would spare patients long steroid courses.
Catalog record
| CREATOR | Xiaoyun Li, Guoxiang Yao, Yujiao Sun, Na Li, Caifeng Gao, Haiping Wang, Rong Wang, Bing Chen |
|---|---|
| YEAR | 2025 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 36 KB |
| VERSION | 1.0 |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |